Early access
Sign in
Not yet taking people in BulgariaPhase 1

Tests pimozide safety in adults with rheumatoid arthritis

Tests whether repeated doses of pimozide are safe for adults with rheumatoid arthritis.

Key facts

Who runs it
Generos Biopharma Ltd.
Where
Sofiya, BulgariaSee the site
Registry title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pimozide after Multiple Dose Administration in Subjects with Rheumatoid Arthritis
Status
Not yet recruiting
Phase
Phase 1
People taking part
24 people, planned
Started
23 Oct 2023
Planned end
31 Dec 2024
Type of study
Interventional
Record updated
20 November 2023

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with rheumatoid arthritis to test the safety and effects of a medicine called pimozide, compared with a placebo.

Age
18 Years and older
Sex
All sexes can join.

Main reasons for not taking part

  • Healthy volunteers cannot join.

Where in Bulgaria

  • Mbal Lyulin EADSofiya, BulgariaNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Tests pimozide safety in adults with rheumatoid arthritisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
20 November 2023